Bayer: Watch 63E
Nicolas Suiffet May 25, 2020 8:39 AM
Bayer, the pharmaceutical group, is nearing deals to resolve 50,000 to 85,000 of 125,000 U.S. cancer lawsuits over the use of its Roundup weedkiller
Bayer, the pharmaceutical group, is nearing deals to resolve 50,000 to 85,000 of 125,000 U.S. cancer lawsuits over the use of its Roundup weedkiller, reported Bloomberg citing people familiar with the matter.
The settlements still need approval from the company’s supervisory board, in June.
Chris Loder, a U.S.-based spokesman for Bayer said “As we have said previously, the company will consider a resolution if it is financially reasonable and provides a process to resolve potential future litigation.”
From a technical perspective, the stock price has landed on a support at 55.3E (Lower Bollinger band + 50DMA) and is posting a rebound. The bullish gap opened above the 20DMA is a positive signal. However, the stock price remains stuck in trading range on a short term basis between 55.3E and 63E.
A breakout confirmation of 63E would confirm the bullish outlook with 68E as target.
Alternatively, a push below 55.3E would reinstate a bearish bias towards 50E.
Source: GAIN Capital, TradingView
GAIN Capital UK Limited (trading as “City Index”) is an execution-only service provider. This material, whether or not it states any opinions, is for general information purposes only and it does not take into account your personal circumstances or objectives. This material has been prepared using the thoughts and opinions of the author and these may change. However, City Index does not plan to provide further updates to any material once published and it is not under any obligation to keep this material up to date. This material is short term in nature and may only relate to facts and circumstances existing at a specific time or day. Nothing in this material is (or should be considered to be) financial, investment, legal, tax or other advice and no reliance should be placed on it.
No opinion given in this material constitutes a recommendation by City Index or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although City Index is not specifically prevented from dealing before providing this material, City Index does not seek to take advantage of the material prior to its dissemination. This material is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.